Category: health equity

MedCity News has assembled compelling speakers to address the Covid-prompted rapid transformation of healthcare at this year’s virtual INVEST conference, April 19-23.

Particularly at the point of care, we have the means and resources to directly inform, educate and offer service to those who have been marginalized across multiple demographic intersections of race, ethnicity and income.

Our industry has committed itself to making our workplaces trusting places to have complex, and sometimes difficult, conversations about diversity and inclusion.

COVID-19 has laid bare racial disparities in the United States health system. For example, COVID-19 cases among Native Hawaiian / Pacific Islanders are up to 2.5 times higher as compared to whites. Similarly, the rate of COVID-19 related deaths among Black Americans and American Indian/Alaskan Natives are twice as high as whites. A recent PhRMA paper finds that gaps in information on race, ethnicity and health are barriers to achieving health equity for many groups.

As part of PhRMA’s continuing work to address health inequities, we are partnering with researchers to study hotspots of COVID-19 and chronic disease inequities in New York state. Reports this summer show that boroughs in New York City with the lowest per-person income and lowest number of employer establishments had the highest COVID-19 mortality rates.

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.

Today, PhRMA released a new report prepared by TEConomy Partners, LLC that provides insights into the efforts of biopharmaceutical companies to advance diversity & inclusion (D&I) in the workplace, in the communities in which they operate and in the patient communities in which they serve. The report examines the state of accelerating demographic changes and persistent workforce disparities both broadly in corporate America and within the biopharmaceutical industry. The report compiles insights into how the biopharmaceutical industry is increasing opportunities and addressing workplace disparities for underrepresented and underserved populations.

This year our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. Outside of the novel coronavirus, major social issues have been brought to the forefront of public discourse. We understand that systematic racism is as real as any disease and our industry is not immune. We need to stand up to racism and injustice because failing to do so impacts our collective wellbeing. Our industry is committed to learning and leading us forward.

Systemic racism is as real as any disease, and our industry is not immune. This summer, in the wake of a national outcry for racial and social justice, our industry offered a firm stance – systemic racism is a disease. As a pharmacist and public health researcher whose motivation stems from advancing health equity – this statement makes me ponder the question, “How can our industry help break the harmful patterns of racial inequities?” One way PhRMA is advocating for health equity is through a Collaborative Actions to Reach Equity (CAREs) grant.

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.

Yesterday, PhRMA published first ever industry-wide principles on clinical trial diversity, a new chapter in the already existing “Principles on Conduct of Clinical Trials & Communication of Clinical Trial Results.” These new principles have been approved by the PhRMA Board of Directors and will take effect in April 2021.

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.

Even though Covid-19 is distinct from any health crisis the country has previously faced, assessing U.S. public health strategies during past crises can provide insight into what has contributed to a more or less equitable response.

Critics have faulted some technologies for potentially reinforcing racial inequality. But a Deloitte exec painted a more optimistic picture at the HLTH conference.

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities.

Today, we are pleased to welcome a guest post from Jason Resendez who is the executive director of the UsAgainstAlzheimer’s Center for Brain Health Equity and head of the LatinosAgainstAlzheimer’s Coalition, convened by UsAgainstAlzheimer’s.

Fifty-two years ago, President Lyndon B. Johnson established a week every September to celebrate the important contributions made by the Latino community. He also sought to address racial injustice and health inequities through landmark legislation and policies such as Medicaid, Medicare and the Civil Rights Act. Unfortunately, our nation and Latino community is still grappling with many of these same issues today. The failure to adequately address social inequities is plaguing communities of color.

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.

Today, we are pleased to welcome a guest post from Dr. Leah Zullig, an associate professor at the Duke School of Medicine in Population Health Sciences, who is dedicated developing, evaluating and implementing approaches to support patients with taking their medications.

In rearchitecting the system by training every care provider in every specialty, and enable lower-cost providers and communities, we will provide a new model of care where a physician isn’t the person who helps us when we’re sick — they help us be healthy.

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Eduardo Cetlin, President, Amgen Foundation on the work to bring more STEM opportunities to young people as well as advancing racial equity in STEM education.

This month, PhRMA published our commitment to racial equity and inclusion in the New York Times as well as in the Informer and the AfroAmerican, DC-based, Black-owned newspapers. This public declaration is an important milestone for our industry as we continue to take concrete steps to address systemic racism and work towards a more equitable future.

The post Navigating systemic racism in Canadian healthcare appeared first on Healthy Debate.

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Jay Brown, Human Rights Campaign Foundation’s Senior Vice President of Programs, Research and Training on the importance of recognizing Pride Month and the fight for equality for all.